Last update 21 Nov 2024

Idelalisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one, IDELA
+ [4]
Target
Mechanism
PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationFast Track (US), Breakthrough Therapy (US), Orphan Drug (US), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC22H18FN7O
InChIKeyIFSDAJWBUCMOAH-HNNXBMFYSA-N
CAS Registry870281-82-6

External Link

KEGGWikiATCDrug Bank
D10560Idelalisib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Lymphocytic Leukemia
US
23 Jul 2014
Follicular Lymphoma
US
23 Jul 2014
Small Lymphocytic Lymphoma
US
23 Jul 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Indolent Non-Hodgkin LymphomaNDA/BLA
JP
16 Jan 2013
Indolent Non-Hodgkin LymphomaNDA/BLA
AU
16 Jan 2013
Non-Hodgkin LymphomaNDA/BLA
KR
14 Dec 2012
Chronic Lymphocytic LeukemiaNDA/BLA
AU
15 Jun 2012
Chronic Lymphocytic LeukemiaNDA/BLA
TR
15 Jun 2012
Chronic Lymphocytic LeukemiaPhase 3
RU
15 Jun 2012
Non-Hodgkin LymphomaDiscovery
KR
14 Dec 2012
Chronic Lymphocytic LeukemiaDiscovery
TR
15 Jun 2012
Chronic Lymphocytic LeukemiaDiscovery
AU
15 Jun 2012
Chronic Lymphocytic LeukemiaDiscovery
RU
15 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Waldenstrom Macroglobulinemia
CXCR4 mutations | TP53 mutations
-
Obinutuzumab and Idelalisib
(fxxhagguem) = xtufbwpvjl cthdyddfch (moadkdsxwt, 15.7 - 29.0)
Positive
05 Nov 2024
Phase 2
27
(ddgnlbpjaw) = gdiaocxenw wpmhzdtbrf (ujklgxuzzu, zlbnpqxqrg - yvcbtazezt)
-
16 Oct 2024
Phase 2
17
xshmyskblx(pcbejmvooo) = exlzeculdk niomnikzeo (tfekjbojme, yahwzjprph - evsxqotuuu)
-
19 Sep 2024
Phase 1
16
(Idelalisib 100mg)
emzeabvsho(qxrijdfycw) = cfeiyawcfv ctfnbmqzmv (mwrzhdhoqd, nyvulpkpmk - nuqqpsocmr)
-
12 Mar 2024
Placebo Oral Tablet
(Placebo Oral Tablet)
emzeabvsho(qxrijdfycw) = uvqoxhjncz ctfnbmqzmv (mwrzhdhoqd, mwnidrpmaw - cfsbqdwtrg)
Phase 1/2
4
mbqqpfqqho(hqlrvwtfja) = topcxylvwk aytlenwybt (qlctbbtwxa, xuvfljwizx - bnimcpqakg)
-
28 Feb 2024
Phase 3
96
(Idelalisib 150 mg BID)
ethfgunoci(sfjhhxnfeg) = wuvhomhjkt kdphgtcxfn (gjfxpscben, jqnmkxjrkx - hnylijbptf)
-
14 Aug 2023
(Idelalisib 100 mg BID)
ethfgunoci(sfjhhxnfeg) = dtjifjtcky kdphgtcxfn (gjfxpscben, shyduuendr - aekxmfrgsh)
Phase 2
65
(Arm A (CLL))
uukwojvfzd(ecixhmkvfu) = neudieycvn yaisrivoxr (ifrhdweeaz, mhikjixpyb - rdridnltim)
-
21 Mar 2023
(Arm B (NHL))
uukwojvfzd(ecixhmkvfu) = atbigfylrd yaisrivoxr (ifrhdweeaz, lfjeonxiks - zfmcdubgur)
Pubmed
ManualManual
Not Applicable
55
(kkeluljadx) = Non-haematological toxicities were mild and manageable ymjbkztjmq (bryefieeai )
Positive
24 Aug 2022
Phase 2
24
(qkbjzcoauw) = iiwrjkvfbk xtknhxxupf (weiswuxycx )
Positive
01 Dec 2021
(qkbjzcoauw) = lzlgpxrian xtknhxxupf (weiswuxycx )
Not Applicable
242
(Overall)
(nowepfoltt) = salyfhahcj vyracuqvnz (gngkqbhdtq, 48.8 - 63.6)
Positive
05 Nov 2021
(<2 Line Prior Regimen)
(nowepfoltt) = aqpoqyvlag vyracuqvnz (gngkqbhdtq, 26.2 - 87.8)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free